SABIC (2010) Q2 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2024 earnings summary
8 Jul, 2026Executive summary
Q2 2024 revenue rose to $9.52 billion (SAR 35.72 billion), up 9% quarter-over-quarter and 5% year-over-year, driven by higher sales volumes and improved margins.
Net income reached $582 million (SAR 2.18 billion), up 85% year-over-year and 772% sequentially, with EPS from continuing operations at SAR 0.74.
EBITDA improved to $1.52 billion (SAR 5.70 billion), up 26% quarter-over-quarter and 13% year-over-year, with margin rising to 16%.
Completed Hadeed divestment to PIF, supporting portfolio optimization and chemicals-focused strategy.
Earned a gold medal from EcoVadis, ranking in the top 5% globally for sustainability.
Financial highlights
Revenue: $9.52B (SAR 35.72B) in Q2 2024, up 9% QoQ and 5% YoY; H1 2024 revenue at $18.24B (SAR 68.4B), down 3% YoY.
Net income: $582M (SAR 2.18B) in Q2 2024, up 85% YoY and 772% sequentially; H1 2024 net income at $650M (SAR 3.4B), up 32% YoY.
EBITDA: $1.52B (SAR 5.70B), margin at 16% (up from 14% in Q1 2024).
Free cash flow was negative at -$380M (SAR -1.44B) in Q2 2024, impacted by working capital post-Hadeed deconsolidation.
Net debt/EBITDA improved to -0.09x, maintaining a robust credit rating.
Outlook and guidance
Global GDP growth for 2024 estimated at 2.7%.
CapEx projected at the lower end of $4–5 billion for 2024, with focus on portfolio optimization and sustainability.
Q3 2024 market trends expected to remain unchanged except for consumer goods, which may improve.
Sale of Film & Sheet business expected within twelve months, pending regulatory approvals.
Management assessing impact of new retirement age law on employee benefits.
Latest events from SABIC
- EBITDA and net income rose despite lower revenue, with higher margins and innovation gains.2010
Q4 20249 Jul 2026 - Q3 2024 revenue up 3% YoY, net income rebounded, and major divestments drove portfolio gains.2010
Q3 20241 Jul 2026 - Q1 2025 revenue stable, net loss narrowed, and transformation, growth, and cost-saving initiatives advanced.2010
Q1 20251 Jul 2026 - Revenue fell but EBITDA margin and cash flow remained strong amid persistent overcapacity.2010
Q3 20251 Jul 2026 - Adjusted EBITDA jumped 40% in Q2 2025, but net loss reflects major impairment charges.2010
Q2 20251 Jul 2026 - Adjusted EBITDA rose 25% to $1.1B (SAR 4.15B) despite a 6% revenue drop, driven by cost and pricing gains.2010
Q1 20261 Jul 2026 - Adjusted profits remained resilient and free cash flow rose 17% despite margin pressure.2010
Q4 20255 Mar 2026